CY1106550T1 - Διαδικασια για την παρασκευη σωματιδιων - Google Patents

Διαδικασια για την παρασκευη σωματιδιων

Info

Publication number
CY1106550T1
CY1106550T1 CY20071100570T CY071100570T CY1106550T1 CY 1106550 T1 CY1106550 T1 CY 1106550T1 CY 20071100570 T CY20071100570 T CY 20071100570T CY 071100570 T CY071100570 T CY 071100570T CY 1106550 T1 CY1106550 T1 CY 1106550T1
Authority
CY
Cyprus
Prior art keywords
liquid
particles
temperature
substance
buffer
Prior art date
Application number
CY20071100570T
Other languages
English (en)
Inventor
Goran Eric Sundholm
Mustafa Demirbuker
Saeed Moshashaee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1106550T1 publication Critical patent/CY1106550T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μία διαδικασία για την παρασκευή σωματιδίων μίας ουσίας, όπως μία πρωτείνη ή πολυπεπτίδιο, που περιλαμβάνει: (α) παρασκευή ενός πρώτου υγρού που περιλαμβάνει νερό, την ουσία κι ένα ρυθμιστή, όπου ο ρυθμιστής έχει μία διαλυτότητα στο νερό η οποία ελαττώνεται καθώς αυξάνεται η θερμοκρασία· και (β) επαφή του πρώτου υγρού μ' ένα δεύτερο υγρό που περιλαμβάνει ένα ρευστό αέριο κι έναν οργανικό διαλύτη χρησιμοποιώντας μία τεχνική ρευστού αερίου αντι-διαλύτη (anti-solvent fluid gas technique) υπό συνθήκες θερμοκρασίας και πίεσης που καταλήγουν στην καθίζηση σωματιδίων που περιλαμβάνουν την ουσία, όπου η θερμοκρασία του πρώτου υγρού είναι η θερμοκρασία σημείου θόλωσης του πρώτου υγρού ή πάνω από αυτή όταν το πρώτο υγρό έρχεται σ' επαφή με το δεύτερο υγρό. Επίσης αξιώνονται σωματίδια που προκύπτουν σύμφωνα με τη διαδικασία και οι συνθέσεις που περιέχουν τα σωματίδια.
CY20071100570T 2001-01-26 2007-04-26 Διαδικασια για την παρασκευη σωματιδιων CY1106550T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process
PCT/GB2002/000261 WO2002058674A2 (en) 2001-01-26 2002-01-22 Process for preparing particles

Publications (1)

Publication Number Publication Date
CY1106550T1 true CY1106550T1 (el) 2012-01-25

Family

ID=9907591

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100570T CY1106550T1 (el) 2001-01-26 2007-04-26 Διαδικασια για την παρασκευη σωματιδιων

Country Status (22)

Country Link
US (2) US7108867B2 (el)
EP (1) EP1357901B1 (el)
JP (1) JP4175892B2 (el)
KR (1) KR100853596B1 (el)
CN (1) CN1298312C (el)
AT (1) ATE354352T1 (el)
BR (1) BR0206439A (el)
CA (1) CA2433838A1 (el)
CY (1) CY1106550T1 (el)
DE (1) DE60218285T2 (el)
DK (1) DK1357901T3 (el)
ES (1) ES2281509T3 (el)
GB (1) GB0102075D0 (el)
HK (1) HK1063157A1 (el)
IL (2) IL156720A0 (el)
MX (1) MXPA03006537A (el)
NO (1) NO20033241L (el)
NZ (1) NZ526942A (el)
PT (1) PT1357901E (el)
SI (1) SI1357901T1 (el)
WO (1) WO2002058674A2 (el)
ZA (1) ZA200304953B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040197412A1 (en) * 2002-12-19 2004-10-07 Baxter International, Inc. Process for preparing pharmaceutical formulations using supercritical fluids
DE602004016311D1 (de) * 2003-04-29 2008-10-16 Organon Nv Verfahren zur verfestigung, bei welchem ein anti-lösungsmittel benutzt wird
JP2006525303A (ja) 2003-05-08 2006-11-09 ネクター セラピューティクス ユーケー リミティド 微粒子物質
JP2007507527A (ja) * 2003-09-30 2007-03-29 スフェリックス, インコーポレイテッド 生物学的に活性なナノ粒子治療用因子
US7223445B2 (en) 2004-03-31 2007-05-29 Eastman Kodak Company Process for the deposition of uniform layer of particulate material
US7220456B2 (en) 2004-03-31 2007-05-22 Eastman Kodak Company Process for the selective deposition of particulate material
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
EP2121057A4 (en) * 2007-02-06 2012-10-10 Incept Llc POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
EP2229233B1 (en) * 2007-12-07 2019-10-09 XSpray Pharma AB (publ) Method for the production of particles
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
EP4324475A1 (en) * 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6668652B2 (ja) 2015-09-18 2020-03-18 日本精工株式会社 直動案内装置、直動案内装置用エンドキャップ

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0432232T3 (da) 1989-05-01 1994-01-31 Alkermes Inc Fremgangsmåde til fremstilling af små partikler af biologisk aktive molekyler
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
AU3705799A (en) * 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
GB9828204D0 (en) 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1404438A2 (en) * 2001-07-12 2004-04-07 Eastman Kodak Company A surfactant assisted nanomaterial generation process
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing

Also Published As

Publication number Publication date
CN1298312C (zh) 2007-02-07
EP1357901A2 (en) 2003-11-05
NO20033241D0 (no) 2003-07-17
ZA200304953B (en) 2004-08-25
CN1487825A (zh) 2004-04-07
DE60218285T2 (de) 2007-11-15
KR20030070921A (ko) 2003-09-02
KR100853596B1 (ko) 2008-08-22
PT1357901E (pt) 2007-05-31
JP2004521891A (ja) 2004-07-22
ES2281509T3 (es) 2007-10-01
ATE354352T1 (de) 2007-03-15
WO2002058674A3 (en) 2002-11-21
EP1357901B1 (en) 2007-02-21
WO2002058674A2 (en) 2002-08-01
CA2433838A1 (en) 2002-08-01
US20070009604A1 (en) 2007-01-11
IL156720A (en) 2010-03-28
AU2002225193B2 (en) 2006-07-27
DK1357901T3 (da) 2007-06-04
IL156720A0 (en) 2004-01-04
US7108867B2 (en) 2006-09-19
DE60218285D1 (de) 2007-04-05
US20040058007A1 (en) 2004-03-25
HK1063157A1 (en) 2004-12-17
GB0102075D0 (en) 2001-03-14
NZ526942A (en) 2005-04-29
BR0206439A (pt) 2003-12-30
JP4175892B2 (ja) 2008-11-05
MXPA03006537A (es) 2003-09-22
SI1357901T1 (sl) 2007-08-31
US7829123B2 (en) 2010-11-09
NO20033241L (no) 2003-07-17

Similar Documents

Publication Publication Date Title
CY1106550T1 (el) Διαδικασια για την παρασκευη σωματιδιων
CY1117625T1 (el) Διαλυτα μεταλλαγμενα μορια ctla4 και χρησεις αυτων
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
Machold et al. Resolution of the light-harvesting chlorophyll ab-protein of Vicia faba chloroplasts into two different chlorophyll-protein complexes
ATE533514T1 (de) Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
CY1113512T1 (el) Διαταξη περιλαμβανουσα ενα ηλεκτροδιο με νανοεπικαλυψη για την παρασκευη ενος πολυ σταθερου υδατικου διαλυματος και μεθοδος παραγωγης αυτου του υδατικου διαλυματος
HUP9801400A2 (hu) Poli-szukcinimid előállítása szerves közegben
ZA200201032B (en) Monomeric protein of the TG-β family.
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
OHNISHI et al. Extraction of actin-and myosin-like proteins from liver mitochondria
ATE386821T1 (de) Zusammensetzungen und methoden zur detektion von humanem immundefizienz virus 2 (hiv-2)
DE69224988D1 (de) Aminosäurederivat und bromacetyl-modifizierte peptide
DK1465663T3 (da) Brugsfærdige paracetamol-injektionsoplösninger som indeholder propylenglycol som det eneste CO-oplösningsmiddel
WO2005014723A8 (en) Cyanin-type compounds having an alkynyl linker arm
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
BR0108791A (pt) Composto cìclico, processo para sua preparação, composição farmacêutica, seu uso e embalagem comercial
ATE255921T1 (de) Keramic-polymer-zusammensetzungen
Yang et al. Bioinspired Load‐Bearing Hydrogel Based on Engineered Sea Anemone Skin‐Derived Collagen‐Like Protein
DE60229966D1 (de) Diabetesmodell
ES387966A1 (es) Procedimiento para componer preparaciones estables de pro- ductos de reaccion solubles o dispersables en agua.
DE60109212D1 (de) Herstellung von warfarin-natrium aus warfarin-säure
KR830009077A (ko) 푸란 유도체의 제조방법
ATE439343T1 (de) Verbessertes verfahren zur zubereitung von gabalactam
ATE524484T1 (de) In vitro verfahren zur sequenzspezifischen biotinylierung von polypeptiden